jetzt noch günstig mit 80 Mio Marktkapitalisierung (Seite 7)

[Schaeffi]

ein Aufmunterungsversuch aus Yahoo Message Board geklaut

tursta • 17 hours ago Flag
31users liked this postsusers disliked this posts2Reply
Remember when the dust settles.....
We will still have Vincent Milano and his track record for growing a company in value and finding a buyer
We will still have Sudhir Agrawal and his years of research in mechanisms of immunotherapy
We will still have Joanna Horobin and her experience in successful commercialization of agents
We will still have 2 platforms with vast and versatile potential
We will still have TLR agonists
We will still have TLR antagonists
We will still have 3GA, which is likely more potent and less toxic than the very successful 2nd generation that we sold.
We will still have multiple preclinical trials showing marked tumor reduction and the abscopal effect
We will still have MDA, the melanoma trial, and IMO-2125.
We will still have the plans for further combination trials with IMO-2125 with a variety of other agents and cancers.
We will still have GSK partnership for renal and 3GA and their (and others) likely interests in other indications
We will still have positive data on IMO-8400 in WM even when MTD has not been reached yet.
We will still have IMO-8400 in DLBCL and excited clinicians that think this will act quickly when time is critical
We will still have NLRP3, DUX4 and interstitial cystitis, uveitis, and facioscapulohumeral muscular dystrophy (FSHD) targets
We will still have IMO-9200 to partner out for lucrative autoimmune indications
We will still have ongoing clinical trials with results in 2016 and 2017
We will still have the Baker's strong backing and 2 board seats
We will still have investors that hold tight and weather this storm
When we have days like this...
We will still have the same reasons why we invested in IDRA in the first place

[Schaeffi]

Kurs sieht shit aus aber das wird schon wieder
es gibt Zeiten zum Sähen und Zeiten zum Ernten

vielleicht hilft das noch auf die Sprünge….


http://sleekmoney.com/idera-pharmaceuticals-inc-nasdaqidra-g…

Idera Pharmaceuticals Inc (NASDAQ:IDRA) Given Average Rating of “Strong Buy” by Brokerages
Investment Analysts’ Updated EPS Estimates for May, 5th (ABC, ACUR, ADRO, APLP, ATTU, AXLL, BFAM, BITE, BLKB, BMY)
Zacks: Five Star Quality Care, Inc. (NYSE:FVE) Receives Average Recommendation of “Strong Buy” from Analysts
Genpact Limited (G) Releases Earnings Results
Investment Technology Group (ITG) Announces Earnings Results
Veeco Instruments Inc. (VECO) Issues Q2 Earnings Guidance
Ameresco Inc (AMRC) Issues Earnings Results, Beats Estimates By $0.11 EPS
Fox Factory Holding Corp (FOXF) Updates Q2 Earnings Guidance
Idera Pharmaceuticals Inc (NASDAQ:IDRA) Given Average Rating of “Strong Buy” by Brokerages

Posted on May 5, 2016 by Jamal Genner in Investing, Zacks Consensus Ratings
Tweet
Idera Pharmaceuticals logoShares of Idera Pharmaceuticals Inc (NASDAQ:IDRA) have earned an average broker rating score of 1.00 (Strong Buy) from the four brokers that cover the company, Zacks Investment Research reports. Four equities research analysts have rated the stock with a strong buy recommendation.

Brokers have set a 12-month consensus price target of $5.33 for the company and are forecasting that the company will post ($0.11) EPS for the current quarter, according to Zacks. Zacks has also assigned Idera Pharmaceuticals an industry rank of 170 out of 265 based on the ratings given to its competitors.

Idera Pharmaceuticals (NASDAQ:IDRA) traded down 2.01% during trading on Thursday, hitting $1.46. The stock had a trading volume of 378,012 shares. Idera Pharmaceuticals has a 52-week low of $1.42 and a 52-week high of $4.42. The company has a 50-day moving average price of $1.89 and a 200-day moving average price of $2.48. The company’s market cap is $172.79 million.
…
..
.

[Schaeffi]

hier mal dir Pipe für die Interessierten.

auch DUX4 ist sehr vielversprechend, was man so liest!

Ist natürlich ein High Risk Wert!
Normahl habe ich keine P1/2 Bios, aber hier mach ich ne Ausnahme:

-Baker Brothers dick mit im Boot
-GSK Partnership
-gute Studien Ergebnisse

natürlich haben hier die MM, Shorts,... wie bei vielen Bios den Finger dick drauf…
but Science always wins

[Schaeffi]

sehe hier schöne Kaufkurse unter 2USD

die letzten News vor dem NBI Downtrend waren bestens
falls der NBI einen Doppleboden bildet und wieder steigt bin ich hier SEHR zuversichtlich
und es kann immer eine GUTE News oben drauf noch kommen

ausserdem:
Aktuell aus Yahoo Board
Milano bought 40k shares

habe alle verkauften shares wieder zurückgekauft

S.

[Schaeffi]

Antwort auf Beitrag Nr.: 51.402.231 von Schaeffi am 03.01.16 20:29:37

sogar Godemode befasst sich schon mit der kleinen IDERA

*********
Mittwoch, 09.12.2015 - 18:29 Uhr
IDERA PHARMA - Kursverdoppelung nicht unrealistisch

2015 war ein verlorenes Jahr für Anleger der Idera Pharma-Aktie. Erst seit dem Herbst zeigen sich die Käufer wieder, die jetzt ein entscheidendes Signal auslösen konnten.

André Rain - Technischer Analyst und Trader bei GodmodeTrader
André Rain
Technischer Analyst und Trader bei GodmodeTrader
André Rain auf Guidants folgen
Idera Pharmaceuticals Inc. - Kürzel: HXXA - ISIN: US45168K3068
Börse: NASDAQ / Kursstand: 4,110 $ (NASDAQ)
ANZEIGE

Die Idera Pharma bricht in dieser Woche unter hohen Umsätzen über die Hochs der letzten Monate sowie die Abwärtstrendlinie seit 2014 aus. Damit wird die dreiecksförmige Handelsspanne seit 2014 nach oben hin aufgelöst. Der heutige Rücksetzer bringt die Aktie zurück an die gebrochene Linie.

Im Idealfall startet jetzt eine größere Aufwärtswelle, welche die Aktie in den kommenden Monaten bis 5,48 und zum 2014er Hoch bei 6,874 USD tragen könnte. Darüber hinaus ist langfristig Platz bis mindestens 11,50 - 12,00 $. Tiefer als 3,15 USD sollte der Titel möglichst nicht mehr per Wochenschlusskurs zurückfallen, dann wäre das Rallyszenario hinfällig.
*************************
na ja grad bei 3 USD!!
könnte bald rauf oder runter gehen
im Ernst sehe NK Gelegenheit am unteren Trendkanal bei ca. 2,75USD

[Schaeffi]

Idera Pharmaceuticals Inc (IDRA) Short Interest Update

Posted on January 2, 2016 by Stefani Robinson in Investing, Options Articles
Tweet
Idera Pharmaceuticals logoIdera Pharmaceuticals Inc (NASDAQ:IDRA) saw a significant drop in short interest in December. As of December 15th, there was short interest totalling 15,297,803 shares, a drop of 8.9% from the November 30th total of 16,786,843 shares, AnalystRatings.NET reports. Currently, 13.1% of the company’s stock are sold short. Based on an average daily volume of 2,351,423 shares, the short-interest ratio is currently 6.5 days.

An institutional investor recently raised its position in Idera Pharmaceuticals stock. Jennison Associates raised its position in Idera Pharmaceuticals Inc (NASDAQ:IDRA) by 0.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The hedge fund owned 2,170,164 shares of the company’s stock after buying an additional 12,823 shares during the period. Jennison Associates owned approximately 1.83% of Idera Pharmaceuticals worth $7,270,000 as of its most recent filing with the SEC.

**************************
Shorts bekommen Angst
**************************
und

hier ne Meinung aus Yahoo:
Massive Potential
It seems more and more things are being discovered that TLR's directly impact. I did not know, for example, that there is evidence that TLR9 antagonism may be able to inhibit preterm labor. Here is a quote from an article I just read:

"The inventors have therefore recognised that agents which inhibit activation of the Toll-like Receptor 9 by fetal DNA, which block the intracellular signalling mediated by Toll-like Receptor 9 following fetal DNA mediated activation, or which block Toll-like Receptor 9 mediated activation of the innate immune response, for example by inhibiting the pro-inflammatory immune response can be used to provide a novel clinical treatment for the prevention of the onset of preterm labor during pregnancy or for the prevention of premature labor."

This article was published in 2015 and described a method for treating preterm labor using chloroquine (which is known to block some TLR's - another piece of information which I did not know). The article was published in an effort by the authors to patent their method of treating preterm labor with chloroquine. I know another company with likely a better and cleaner inhibitor of TLR 9...

[Schaeffi]

Antwort auf Beitrag Nr.: 51.157.074 von Schaeffi am 23.11.15 19:27:05

Idera Pharmaceuticals Reports Positive Data From Ongoing Phase 1/2 Clinical Trial of IMO-8400 at #ASH2015

Charles Gross , Benzinga Staff Writer FOLLOW
December 06, 2015 8:39am


Idera Pharmaceuticals, Inc.
IDRA 3.83%
presented on Saturday, initial clinical data from its ongoing Phase 1/2 clinical trial for IMO-8400, a Toll-like receptor 7, 8 and 9 antagonist, being evaluated for the treatment of patients with relapsed or refractory Waldenström's Macroglobulinemia (WM). These results provide evidence that IMO-8400 has clinical activity and is well tolerated. Today's results were presented during a poster session (Abstract #1540) at the 57th Annual Meeting of the American Society of Hematology (ASH) in Orlando, FL.
"Our clinical trial in Waldenström's Macroglobulinemia represents the first step in our understanding of the potential role that TLR antagonism could play in B-cell malignancies, specifically in those harboring the MYD88-L265P oncogenic mutation which is highly prevalent in Waldenström's Macroglobulinemia," stated Vincent Milano, Idera's Chief Executive Officer. "We are pleased that the initial results from this ongoing trial met our objectives in determining safety and tolerability, as well as clinical activity of IMO-8400 in this patient population. We are further encouraged that the safety profile seen to date will enable us to evaluate higher dosing levels of IMO-8400.
…
..
.


und wieder was pos. zu berichten.
müsste sich auch auf den Kurs am Montag so auswirken

[Schaeffi]

Antwort auf Beitrag Nr.: 51.075.861 von Schaeffi am 12.11.15 19:46:49

BIOFLASH Idera shares jump on new partnership with GSK for kidney disease drugs Nov 23, 2015, 11:06am EST

Shares of Idera Pharmaceuticals jumped today on a new partnership with London drug giant GlaxoSmithKline potentially worth $100 million in milestone payments plus royalties on drugs for kidney diseases.
SPONSORED BY
PEOPLE ON THE MOVE
Jim Fiorentino
Jim Fiorentino
Bluestone Energy Services
Ashutosh Aman
Ashutosh Aman
Lendlease
SPONSORChristopher J. O'Connell
Christopher J. O'Connell
Webster Bank
See More People on the Move
Cambridge-based Idera (Nasdaq: IDRA) will get $2.5 million up front in the deal, adding to the $95 million it reported as of Sept. 30. But in addition to the $100 million in regulatory and development milestone payments, the small Cambridge biotech stands to get royalties from GSK (NYSE: GSK) of up to 5 percent on future royalties, which the company estimates as “in excess of $500 million.”

…
..
.

i love this Stock

[Schaeffi]

Home Biotechs Here’s Why Markets Overlooked Idera’s Financials

By Jennifer Aldershot - November 12, 2015
Share on Facebook Tweet on Twitter
On August 6, 2015, Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) reported a third quarter loss of $11.3 million. Despite the loss, the company gained strength, and is currently trading at a circa 10% premium to its pre-announcement market capitalization. At first glance, this seems counterintuitive. However, a closer inspection reveals the market’s reasoning, and presents an intriguing opportunity for an exposure to the oncology and rare disease space. Here’s why.

First, what’s Idera. The company is a clinical stage biotech with a current focus on using toll like receptor antagonists in oncology indications. Its primary pipeline candidate is called IMO-8400. As mentioned, it is a TLR antagonist, which means it inhibits the signaling pathway of TLRs. TLRs are what are responsible for initiating an immune response in a wide variety of situations, so why would you want to inhibit this process? Well, in the indications Idera is targeting, the immune response is to create more cytokines – toxic cytokines – that cause the cells of whatever is causing the damage to replicate. By inhibiting the TLR signaling pathway in pathogenic tissue, the immune response doesn’t happen and the initial cells don’t replicate. That’s the essence of it anyway.

Idera is currently trialing IMO 8400 in a phase 1/2 clinical trial for a Waldenström’s Macroglobulinemia (WM) indication. WM is a rare type of B-cell lymphoma that is – at present – totally incurable. The day before the financials announcement, the company announced it is set to present data from the trial at the 2015 American Society of Hematology annual meeting, which is set to take place from December 5 to December 8 in Orlando. That Idera intends to present the data at the meeting suggests it is positive (otherwise there is no incentive to parade it in front of sector experts), and this suggests we could see some demonstration of efficacy from the trial. The company has said it also intends to bring safety and tolerability into the presentation, meaning we will be able to get an idea of the all round profile of the drug – a good thing at this early stage. It is only a small trial, 19 patients enrolled and dosed, but in a rare disease like this (1000-1500 new cases a year) small trials will often be enough to get a drug to the next stage of the development process, purely based on the fact that there is not a large enough patient population sample to conduct a bigger trial.

Just this week, Idera also announced it had kicked off the enrollment phase of a phase 2 for a second indication – dermatomyositis. Dermatomyositis is an inflammatory skin and muscle disease, in which the immune response elicited by the TLRs translates to an overproduction of inflammatory cytokines, adding to the inflammation. By inhibiting the production of these inflammatory cytokines, just as with its WM indication, the company hopes it can reduce and negate the symptoms of the disease. This one has a larger patient population in the US – somewhere circa 20,000 – and so the sample size for the trial is larger at 48 patients across 20 US centers. We don’t know exactly when top line is expected, but the trial is 24 weeks’ worth of dosing. Taking into account time necessary for recruiting the patients, we are probably looking at top line somewhere during the second half of next year – likely fourth quarter.

So that’s why the company is gaining strength. It got hammered over the last few months in the wake of the wider market decline, but with the data presentation a near term catalyst and the initiation of a fresh indication trial, there is plenty to keep it in the spotlight going forward. If it can maintain a positive track record in the ongoing trials, we could be looking at a phase 3 in its initial indication (WM) before second quarter next year. It’s a rare disease, currently with no available treatment, making it eligible for both orphan and breakthrough designations. If we get these, keep an eye on status updates as potential upside catalysts. Keep in mind that the company may need financing to complete a phase 3, if we get to that stage. Cash on hand comes in around $35 million, down from $92 million at the end of second quarter, and costs are likely to inflate in the wake of the second indication trial. Any financing will likely dilute the holdings of an early stage investor – not something that should necessarily negate an investment (it happens a lot in biotech) but something to consider when weighing up the risks. Roll on December.

bin immer noch dabei und bleibe - mit meinen restlichen Freeshares

[Schaeffi]

Antwort auf Beitrag Nr.: 49.859.239 von Schaeffi am 27.05.15 18:51:47

Idera to Present at Two June Investor Healthcare Conferences

http://www.nasdaq.com/press-release/idera-to-present-at-two-…